Literature DB >> 28341237

ACTIVLIM-CP a new Rasch-built measure of global activity performance for children with cerebral palsy.

Yannick Bleyenheuft1, Julie Paradis2, Anne Renders3, Jean-Louis Thonnard4, Carlyne Arnould5.   

Abstract

OBJECTIVE: Children with cerebral palsy (CP) often have upper extremity (UE) and lower extremity (LE) impairments. While tools measuring separately UE and LE abilities are currently used, activities in which UE and LE are used in combination - numerous in everyday life - cannot be assessed because no instrument allows capturing global activity performance in children with CP. This study aimed to develop a clinical tool for measuring their global activity performance using the Rasch model. STUDY
DESIGN: The caregivers of 226 children with CP (2-18 years old) answered a 154-item experimental questionnaire. Within 4-6 weeks, 129 of them filled in the questionnaire a second time. Responses were analyzed using the Rasch RUMM2020 software.
RESULTS: The final 43 item scale presented a high reliability (R=0.98) and reproducibility (R=0.97). The item difficulty hierarchy was consistent over time and did not vary according to age, gender, or clinical form, allowing the follow-up of children from 2 to 18 years old.
CONCLUSIONS: ACTIVLIM-CP is a unidimensional scale specifically developed to measure global activity performance in children with CP providing a reliable tool to follow children's evolution and document changes related to neurorehabilitation, especially where a combination of UE and LE is targeted. Its responsiveness is still to be tested.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Activity; Cerebral palsy; Lower extremity+Rasch-model (outside Mesh); Upper extremity

Mesh:

Year:  2016        PMID: 28341237     DOI: 10.1016/j.ridd.2016.10.005

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  4 in total

1.  Preschool HABIT-ILE: study protocol for a randomised controlled trial to determine efficacy of intensive rehabilitation compared with usual care to improve motor skills of children, aged 2-5 years, with bilateral cerebral palsy.

Authors:  Leanne Sakzewski; Sarah Reedman; Kate McLeod; Megan Thorley; Andrea Burgess; Stewart Trost; Matthew Ahmadi; David Rowell; Mark Chatfield; Yannick Bleyenheuft; Roslyn N Boyd
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

2.  Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies.

Authors:  Alicia Alonso-Jiménez; Esther Fernández-Simón; Daniel Natera-de Benito; Carlos Ortez; Carme García; Elena Montiel; Izaskun Belmonte; Irene Pedrosa; Sonia Segovia; Patricia Piñol-Jurado; Ana Carrasco-Rozas; Xavier Suárez-Calvet; Cecilia Jimenez-Mallebrera; Andrés Nascimento; Jaume Llauger; Claudia Nuñez-Peralta; Paula Montesinos; Jorge Alonso-Pérez; Eduard Gallardo; Isabel Illa; Jordi Díaz-Manera
Journal:  Front Neurol       Date:  2021-06-11       Impact factor: 4.003

3.  Protocol of changes induced by early Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (e-HABIT-ILE) in pre-school children with bilateral cerebral palsy: a multisite randomized controlled trial.

Authors:  Rodrigo Araneda; Stephane V Sizonenko; Christopher J Newman; Mickael Dinomais; Gregoire Le Gal; Daniela Ebner-Karestinos; Julie Paradis; Anne Klöcker; Geoffroy Saussez; Josselin Demas; Rodolphe Bailly; Sandra Bouvier; Emmanuel Nowak; Andrea Guzzetta; Inmaculada Riquelme; Sylvain Brochard; Yannick Bleyenheuft
Journal:  BMC Neurol       Date:  2020-06-12       Impact factor: 2.474

4.  Functional, neuroplastic and biomechanical changes induced by early Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (e-HABIT-ILE) in pre-school children with unilateral cerebral palsy: study protocol of a randomized control trial.

Authors:  R Araneda; S V Sizonenko; C J Newman; M Dinomais; G Le Gal; E Nowak; A Guzzetta; I Riquelme; S Brochard; Y Bleyenheuft
Journal:  BMC Neurol       Date:  2020-04-14       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.